Truist reiterates Buy on Scholar Rock stock, $77 target on launch
Truist Securities reiterated a Buy rating and $77 price target for Scholar Rock (SRRK) after a management roadshow, citing confidence in the team and strong demand for its spinal muscular atrophy treatment. The stock trades at $41.40, with analysts' targets ranging from $58 to $84. The company resubmitted a Marketing Authorization Application in the EU, and other analysts have also raised their price targets.
How this was made
The 30-second read
Why it matters
Analyst rating changes can move the stock modestly, but no new corporate action or clinical data were disclosed.
Market read
The article provides an analyst rating update that may generate modest buying interest in SRRK.
What to watch
Potential regulatory setbacks or slower adoption could keep the stock volatile despite the higher target.
Background
Truist's reiteration follows a management roadshow and includes updated pricing assumptions for the ISEMBYLD therapy.
Ticker impact
Truist Securities reiterated a Buy rating and raised its price target to $77 for Scholar Rock (SRRK) after a non‑deal roadshow with senior management.
potential upward pressure as investors price in the higher target
The new target is substantially above the current price, but the news is an analyst reiteration rather than a fresh corporate event.
Market effects
May lift sentiment in the biotech/rare‑disease sector as peers see similar analyst upgrades.
Limited to US biotech investors.
Low global impact.
Counterpoint
The price target assumes successful launch of ISEMBYLD; execution risk remains high and profitability is still distant.
Key entities
- companyScholar Rock
Biotech firm developing rare‑disease therapies, ticker SRRK.
- analystTruist Securities
Investment bank providing the rating and price target.
